BRD2 and infection: Despite the current screening practices, post-blood transfusion HBV infection still persists[29,30], most probably due to the serologically negative window period (more so during the late stages of infection)[31], or through treatment[26]; all of which highlight the need for HBcAb screening and NAT in China.